Accuray (ARAY) Return on Capital Employed (2011 - 2026)
Accuray's (ARAY) quarterly Return on Capital Employed came in at 23.7% in Q1 2026, down 6421.0% year-on-year from 0.37% in Q1 2025, and up 21.8% quarter-over-quarter from 30.31% in Q4 2025.
Accuray (ARAY) Return on Capital Employed (2011 - 2026) Analysis & Trends
Accuray's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 23.7% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 6421.0% year-over-year to 23.7% in Q1 2026; TTM through Mar 2026 was 23.7%, a 6421.0% decrease from a year earlier, with the FY2025 full-year figure at 5.73%, up 266.0% from the prior year.
- Return on Capital Employed improved to 23.7% in Q1 2026 per ARAY's latest filing, from 30.31% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 58.82% in Q3 2023 and bottomed at 30.31% in Q4 2025.
- The 5-year median for Return on Capital Employed is 23.01% (2023), against an average of 16.9%.
- Across the five-year window, Return on Capital Employed plunged 16462 bps in 2022 and soared 4631 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 47.16% in 2022, then plunged by 48 bps to 24.52% in 2023, then sank by 88 bps to 2.93% in 2024, then tumbled by 1134 bps to 30.31% in 2025, then increased by 22 bps to 23.7% in 2026.
- Per Business Quant, the three latest ARAY Return on Capital Employed figures stand at 23.7% (Q1 2026), 30.31% (Q4 2025), and 1.85% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Accuray | 29,832.96 | -38.50 Mn | 25.29 Mn | -23.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.70% |
| Dec 31, 2025 | -30.31% |
| Sep 30, 2025 | 1.85% |
| Jun 30, 2025 | 8.58% |
| Mar 31, 2025 | 40.51% |
| Dec 31, 2024 | 2.93% |
| Sep 30, 2024 | -25.18% |
| Jun 30, 2024 | -19.60% |
| Mar 31, 2024 | -5.80% |
| Dec 31, 2023 | 24.52% |
| Sep 30, 2023 | 58.82% |
| Jun 30, 2023 | 23.20% |
| Mar 31, 2023 | 23.01% |
| Dec 31, 2022 | 47.16% |
| Sep 30, 2022 | 49.11% |
| Jun 30, 2022 | 57.52% |
| Mar 31, 2022 | 54.74% |
| Dec 31, 2021 | 86.22% |
| Sep 30, 2021 | 213.73% |
| Jun 30, 2021 | 127.66% |